
Celldex Therapeutics CLDX
$ 31.48
1.35%
Annual report 2025
added 02-25-2026
Celldex Therapeutics Operating Cycle 2011-2026 | CLDX
Annual Operating Cycle Celldex Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 321 | 86.5 | 78.9 | 40.2 | 77.5 | 69.3 | - | - | - | - | - | - | 43.4 | 1.43 | 6.7 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 321 | 1.43 | 80.5 |
Quarterly Operating Cycle Celldex Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 72.1 | 116 | - | 34.1 | 76.8 | 1.55 K | - | 11.1 | 244 | 78.4 | - | 32.1 | 95.2 | 109 | - | 207 | 30.5 | 242 | 43.4 | 246 | 697 | 47.1 | 104 | 170 | 130 | 134 | 164 | 307 | 104 | 56.5 | 49.6 | 43.7 | 44.8 | 109 | 86.9 | 73.3 | 117 | 96.4 | 49.5 | 86.3 | 40.6 | 131 | 26.4 | 35.4 | 65.8 | 100 | 72 | 45.5 | 460 | 10.1 | 1.1 | 1.29 | 2 | 4.01 | 6.38 | 6.56 | 7.95 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.55 K | 1.1 | 130 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akebia Therapeutics
AKBA
|
210 | $ 1.35 | -2.17 % | $ 347 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
102 | $ 330.71 | 3.72 % | $ 43.3 B | ||
|
Altimmune
ALT
|
7.85 K | $ 3.47 | 3.89 % | $ 306 M | ||
|
Amgen
AMGN
|
282 | $ 346.45 | -0.43 % | $ 186 B | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Amneal Pharmaceuticals
AMRX
|
117 | $ 12.37 | -0.92 % | $ 3.88 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Anika Therapeutics
ANIK
|
325 | $ 15.0 | 1.32 % | $ 220 M | ||
|
ANI Pharmaceuticals
ANIP
|
295 | $ 76.34 | 2.87 % | $ 1.47 B | ||
|
Aptorum Group Limited
APM
|
4.89 | $ 0.92 | -1.11 % | $ 5.02 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Aquestive Therapeutics
AQST
|
223 | $ 4.15 | 0.48 % | $ 444 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.43 | 4.98 % | $ 231 M | ||
|
Ardelyx
ARDX
|
1.05 K | $ 6.08 | 2.27 % | $ 1.47 B | ||
|
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | ||
|
Arcutis Biotherapeutics
ARQT
|
291 | $ 23.93 | 1.27 % | $ 3.04 B | ||
|
Arvinas
ARVN
|
4.66 | $ 11.11 | 2.4 % | $ 788 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 61.57 | 0.88 % | $ 8.24 B | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Assembly Biosciences
ASMB
|
25.1 | $ 30.01 | 3.43 % | $ 336 M | ||
|
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Atossa Therapeutics
ATOS
|
249 | $ 5.21 | -2.89 % | $ 44.9 M | ||
|
Atara Biotherapeutics
ATRA
|
4.13 | $ 5.03 | 0.7 % | $ 63.1 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
659 | $ 16.04 | 2.75 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
129 | $ 1.42 | 0.35 % | $ 378 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B |